IP Library Granted Patent US 7,465,585
Granted Patent B1
US 7,465,585 · App. 11/786,146 · Granted Dec 16, 2008

Compositions and methods for inhibiting cell migration

Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,465,585
App. No.
11/786,146
Granted
Dec 16, 2008
Kind
B1
Abstract

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.

Claims (9)

1. A method of mobilizing cells comprising contacting the cells with an effective amount of a fragment of Dickkopf-1 (Dkk1) protein of the formula: set forth in SEQ ID NO:4.

2. The method of claim 1 , wherein the cells express endogenous Dkk1.

3. The method of claim 2 , wherein the cells do not express endogenous Dkk1 protein.

4. The method of claim 1 , wherein the cells contacted with the fragment migrate to the site of a wound.

5. A method of mobilizing cells comprising contacting the cells with an effective amount of human Dickkopf-1 (Dkk1) protein set forth as SEQ ID NO:5 comprising a mutation in the amino terminal cysteine rich domain (CRD) and a mutation in the carboxy-terminal CRD.

6. The method of claim 5 , wherein the Dkk1 protein comprises a mutation at residues 124 and 194.

7. The method of claim 6 , wherein the Dkk1 protein comprises aspartate at residue 124 and alanine at residue 194.

8. The method of claim 5 , wherein the cells do not express endogenous Dkk1 protein.

9. The method of claim 1 , wherein the cells contacted with the Dkk1 protein migrate to the site of a wound.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 16, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060813/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2007
From: MERCOLE, MARK; GUPTA, RUCHIKA
To: BURNHAM INSTITUTE, THE
Reel/Frame 019599/0469 →
Continuity (1)
Provisional Application 6079063500 · Apr 10, 2006